Trial register facet
Trial records reported in 2020
16 records with a recorded report or completion year of 2020.
Showing 0 records on this page
Records
16 documents
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| AWARD-11 | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, active-controlled | 1,842 | 2020 | High |
| AWARD-11-BODY-COMPprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2020 | Very low |
| AWARD-11-ELDERLYprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2020 | Very low |
| AWARD-11-QOLprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2020 | Very low |
| AWARD-11-REGIONAL-CNprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2020 | Very low |
| AWARD-11-REGIONAL-JPprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2020 | Very low |
| SCALE-TEENS | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 251 | 2020 | Moderate |
| SCALE-TEENS-BODY-COMPprogramme record | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2020 | Very low |
| SCALE-TEENS-DDIprogramme record | Liraglutide | Phase 1 | Reported | Randomised crossover | — | 2020 | Very low |
| SCALE-TEENS-HEPATIC-IMPprogramme record | Liraglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2020 | Very low |
| SCALE-TEENS-PKprogramme record | Liraglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2020 | Very low |
| SCALE-TEENS-RENAL-IMPprogramme record | Liraglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2020 | Very low |
| TED-PAEDIATRIC | Teduglutide | Phase 3 | Reported | Single-arm open-label | 59 | 2020 | Moderate |
| TED-PAEDIATRIC-BODY-COMPprogramme record | Teduglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2020 | Very low |
| TED-PAEDIATRIC-REGIONAL-CNprogramme record | Teduglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2020 | Very low |
| TED-PAEDIATRIC-REGIONAL-JPprogramme record | Teduglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2020 | Very low |